Clinical Trials - February 15, 2016
Sobi initiates clinical programs and receives US patent
Swedish Orphan Biovitrum has announced that it has decided to initiate two clinical programs with Kineret (anakinra) in North America, with the aim of evaluating two new potential indications for Kineret where a significant need for alternative treatment options exists: acute gout and Still’s disease. An increasing body of evidence suggests the potential involvement of interleukin-1 […]
Pharma Business - August 19, 2015
Approval in Australia for Sobi’s Kineret
Sobi together with its Australian partner, A. Menarini Australia Pty Ltd have received marketing authorisation in Australia for Kineret (anakinra) for the treatment of systemic juvenile idiopathic arthritis (SJIA), which is a rare form of juvenile chronic arthritis. “We are pleased and encouraged by this approval which was achieved through a fruitful collaboration between physicians, […]